FierceBiotech Radio

Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.

Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs.

Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceuticals as a buyout target.

Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.

Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.

Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.

FiercePharmaAsia's Matt Driskill discusses the recent conference call held by Benitec Biopharma in Australia in which interim CEO Greg West explains the rather abrupt departure of CEO Peter French and outlines the company's search for a replacement who can bring deep experience in the American market.

Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a thoughtful consideration of how a certain biotech entrepreneur is bringing attention to an FDA loophole.

In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.

Fierce editors discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering conclusion of two hostile takeovers.

Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.

Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shire's up-and-down efforts to buy stuff it wants.

Fierce editors discuss a fascinating Valeant Pharmaceuticals conference call, Pfizer's desire for a big buyout and the creaky world of biotech IPOs.

Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.

Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.

Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.

Fierce editors discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech bubble, and Bristol-Myers Squibb's interesting televisual choices.

FierceBiotech's John Carroll discusses his personal experience with the ongoing fallout over Turing Pharmaceuticals' drug pricing and CEO Martin Shkreli's public response.

Fierce editors discuss some surprising trial results for a diabetes drug from Eli Lilly and Boehringer Ingelheim, the continued flow of money into private biotech companies, and the public frankness of Roche CEO Severin Schwan.

Fierce editors discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug patents, and a new twist in the buyout battle between Horizon Pharma and Depomed.